Bronchial Thermoplasty - 28/01/19

Doi : 10.1016/j.ccm.2018.10.015

Anne S. Mainardi, MD ^a, Mario Castro, MD ^b, Geoffrey Chupp, MD ^a,^⁎
^a Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, 300 Cedar Street, New Haven, CT 06520, USA
^b Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, 4523 Clayton Avenue, St Louis, MO 63110, USA

^∗Corresponding author. Division of Pulmonary, Critical Care, and Sleep Medicine, PO Box 208057, 300 Cedar Street, New Haven, CT 06520-8057.Division of Pulmonary, Critical Care, and Sleep MedicinePO Box 208057300 Cedar StreetNew HavenCT06520-8057

Résumé

Bronchial thermoplasty is an advanced therapy for severe asthma. It is a bronchoscopic procedure in which radiofrequency energy is applied to the airway wall, resulting in decreased airway smooth muscle burden. Human trials have shown that bronchial thermoplasty may reduce asthma exacerbations and improve quality of life in patients with severe uncontrolled asthma. It has been demonstrated to be a safe procedure, with most adverse events being early and mild. More studies are required to understand the precise effects of bronchial thermoplasty on the asthmatic airway and optimal parameters to appropriately select patients for this novel procedure.

Le texte complet de cet article est disponible en PDF.

Keywords : Bronchial thermoplasty, Radiofrequency ablation, Severe asthma, Airway smooth muscle

Plan

Disclosure Statement: A.S. Mainardi has no financial relationships to disclose. Dr. Castro receives University Grant Funding from NIH, American Lung Association, PCORI. He receives Pharmaceutical Grant Funding from AstraZeneca, Boeringer Ingelheim, Chiesi, GSK, Novartis, Sanofi Aventis. He is a consultant for Aviragen, Boston Scientific, Genentech, Nuvaira, Neutronic, Therabron, Theravance, Vectura, 4D Pharma, VIDA, Mallincrodt, Teva, Sanofi-Aventis. He is a speaker for Astra-Zeneca, Boeringer Ingelheim, Boston Scientific, Genentech, Regeneron, Sanofi, Teva. He receives royalties from Elsevier. G. Chupp reports receiving honoraria for advisory board and speaker bureau activity from Astra Zeneca, Glaxo-Smith-Kline, Genentech, Teva, Boehringer-Ingelheim, and Circassia.

Export

Vol 40 - N° 1

P. 193-207 - mars 2019 Retour au numéro

Article précédent

Immunomodulators and Biologics : Beyond Stepped-Care Therapy
Mauli Desai, John Oppenheimer, David M. Lang

| Article suivant

The Use of Geographic Data to Improve Asthma Care Delivery and Population Health
Margaret E. Samuels-Kalow, Carlos A. Camargo

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Bronchial Thermoplasty - 28/01/19

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL